The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of acoramidis in the EU based on positive results from the ...

The findings could potentially enable patients to be identified and treated before symptoms of ATTR-CM emerge.

Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy, and ...

Bayer AG won the backing of European Union regulators for its cardiology drug as the German company fights to offset the ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended another batch medicines for approval at ...

The U.S. Food and Drug Administration has approved a drug developed at Stanford Medicine that offers hope to people diagnosed ...

BridgeBio Pharma (BBIO) announced the Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion ...

The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for vutrisiran for the treatment of transthyretin amyloidosis with cardiomyopathy (ATTR-CM).

See the new treatment that will break a Pfizer monopoly on a drug for heart disease.

Amyloidosis is a rare, multisystem disease that leads to deposition of misfolded proteins in various organs. This case report ...

The new understanding of molecular events that drive the various forms of amyloidosis has generated treatment strategies that ...

Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive, often fatal disease. Nexiguran ziclumeran (nex-z) is an investigational therapy based on CRISPR-Cas9 (clustered regularly ...